@prefix dc1: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "for the management of schizophrenia trifluoperazine hydrochloride tablets usp are effective for the short term treatment of generalized non psychotic anxiety however trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments i e benzodiazepines when used in the treatment of non psychotic anxiety trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warnings the effectiveness of trifluoperazine hydrochloride tablets as a treatment for non psychotic anxiety was established in a 4 week clinical multicenter study of outpatients with generalized anxiety disorder dsm iii this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non psychotic conditions in which anxiety or signs that mimic anxiety are found i e physical illness organic mental conditions agitated depression character pathologies etc trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation nkg:SymptomaticReliefIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "Hv7/gYcmdaPMB5ytP7IHLV1Qip6Tvo05Re7nF1slSSf/qyGZoYk1im3Z29D1Lm99GXovfr1JDIuuwogYjDZTrFlBDjUVUe+iDth5vgrEQHV3c6N3izNRsasTNZSIIxHiD0xM40DGCK3+0XPMuqcZOMYxCKkj+BiI5fccKlNNyI8=";
npx:hasSignatureTarget this: .
this: dc1:created "2021-06-14T08:56:34.513+02:00"^^xsd:dateTime;
dc1:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}